Eurofins-Cerep SA

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: FR0013256518
EUR
15,800.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Low Debt Company with Strong Long Term Fundamental Strength

 
2

Negative results in Jun 25

3

With ROE of 0.00%, it has a Fair valuation with a 1.24 Price to Book Value

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Miscellaneous

stock-summary
Market cap

EUR 80 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.19

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

1.09

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.24%
0%
-11.24%
6 Months
-13.19%
0%
-13.19%
1 Year
-23.3%
0%
-23.3%
2 Years
-31.3%
0%
-31.3%
3 Years
-35.77%
0%
-35.77%
4 Years
-15.51%
0%
-15.51%
5 Years
12.86%
0%
12.86%

Eurofins-Cerep SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
93.75%
EBIT Growth (5y)
0
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
3.84
Net Debt to Equity (avg)
-0.24
Sales to Capital Employed (avg)
0.49
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
1.24
EV to EBIT
NA
EV to EBITDA
EV to Capital Employed
1.29
EV to Sales
2.94
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Eurofins-Cerep SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.16% vs -7.35% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.26% vs -33.91% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "40.50",
          "val2": "44.10",
          "chgp": "-8.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.10",
          "val2": "8.50",
          "chgp": "-16.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.20",
          "val2": "7.60",
          "chgp": "-5.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "116.80%",
          "val2": "147.30%",
          "chgp": "-3.05%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
40.50
44.10
-8.16%
Operating Profit (PBDIT) excl Other Income
7.10
8.50
-16.47%
Interest
0.00
0.00
Exceptional Items
0.00
-0.00
Consolidate Net Profit
7.20
7.60
-5.26%
Operating Profit Margin (Excl OI)
116.80%
147.30%
-3.05%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -8.16% vs -7.35% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.26% vs -33.91% in Dec 2023

stock-summaryCompany CV
About Eurofins-Cerep SA stock-summary
stock-summary
Eurofins-Cerep SA
Miscellaneous
Eurofins-Cerep SA, formerly Cerep SA is a France-based company that specializes in the pre-clinical research, discovery and development of new pharmaceutical drugs. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The Company then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.
Company Coordinates stock-summary
Company Details
Le bois l'Eveque , CELLE-LEVESCAULT None : 86600
Registrar Details